Real-world effectiveness data of erenumab-treated migraine patients in Switzerland: The SQUARE study

被引：0
|
作者：
Schafer, E. [1 ]
Arzt, M. [1 ]
Meyer, I. [1 ]
Gantenbein, A. [2 ]
机构：
[1] Novartis Pharma Schweiz AG, Neurosci, Rotkreuz, Switzerland
[2] Zurzach Care, Neurol, Bad Zurzach, Switzerland
来源：
CEPHALALGIA | 2021年 / 41卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
AL078
引用
收藏
页码：235 / 236
页数：2
相关论文
共 50 条
  • [11] Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results
    Andreas R. Gantenbein
    Reto Agosti
    Christian P. Kamm
    Gunther Landmann
    Niklaus Meier
    Gabriele Susanne Merki-Feld
    Jens A. Petersen
    Heiko Pohl
    Philippe Ryvlin
    Christoph J. Schankin
    Dragana Viceic
    Chiara Zecca
    Elisabeth Schäfer
    Ina Meyer
    Michael E. Arzt
    The Journal of Headache and Pain, 2022, 23
  • [12] Swiss Quality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results
    Gantenbein, Andreas R.
    Agosti, Reto
    Kamm, Christian P.
    Landmann, Gunther
    Meier, Niklaus
    Merki-Feld, Gabriele Susanne
    Petersen, Jens A.
    Pohl, Heiko
    Ryvlin, Philippe
    Schankin, Christoph J.
    Viceic, Dragana
    Zecca, Chiara
    Schaefer, Elisabeth
    Meyer, Ina
    Arzt, Michael E.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01):
  • [13] Risk of Hypertension in Erenumab-treated Patients With Migraine in Clinical Trials and in the Postmarketing Setting
    Dodick, David
    Ailani, Jessica
    Tepper, Stewart
    Pannacciulli, Nico
    Navetta, Marco
    Xue, Fei
    Zhang, Feng
    Choudhry, Jessica
    NEUROLOGY, 2021, 96 (15)
  • [14] Risk of hypertension in erenumab-treated patients with migraine in clinical trials and in the postmarketing setting
    Dodick, D. W.
    Ailani, J.
    Tepper, S. J.
    Pannacciulli, N.
    Navetta, M.
    Xue, F.
    Zhang, F.
    Choudhry, J.
    HEADACHE, 2021, 61 : 107 - 107
  • [15] Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE
    Alsaadi, Taoufik
    Noori, Suzan
    Varakian, Razmig
    Youssef, Saly
    Almadani, AbuBaker
    BMC NEUROLOGY, 2022, 22 (01)
  • [16] Final results of the SPECTRE study: real-world data giving an insight into the treatment of migraine patients with erenumab in Germany
    Gaul, Charly
    Koch, Mirja
    Weiss, Cordula
    NEUROLOGY, 2023, 100 (17)
  • [17] Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE
    Taoufik Alsaadi
    Suzan Noori
    Razmig Varakian
    Saly Youssef
    AbuBaker Almadani
    BMC Neurology, 22
  • [18] Real-world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real-world study
    Gladstone, Jonathan
    Chhibber, Sameer
    Minhas, Jagdeep
    Neish, Calum S.
    Power, G. Sarah
    Lan, Zhiyi
    Rochdi, Driss
    Lanthier-Martel, Jessica
    Bastien, Natacha
    HEADACHE, 2022, 62 (01): : 78 - 88
  • [19] Effectiveness and safety of erenumab, galcanezumab and fremanezumab in migraine: real world data results
    Castano-Amores, C.
    Nieto-Gomez, P.
    Alvarez-Sanchez, R.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2022, 44 (03) : 819 - 820
  • [20] Real-world effectiveness and tolerability of erenumab: A retrospective cohort study
    Kanaan, Saad
    Hettie, Gabrielle
    Loder, Elizabeth
    Burch, Rebecca
    CEPHALALGIA, 2020, 40 (13) : 1511 - 1522
12345